AML is More Common in Older Individuals
Acute myeloid leukemia (AML) is significantly more common in older individuals compared to chronic myeloid leukemia (CML), with AML having a median age at diagnosis of 67-71 years and representing the most common form of acute leukemia among adults. 1
Epidemiological Evidence
AML Age Distribution
The most recent ESMO guidelines (2020) clearly establish that AML incidence is age-dependent, rising markedly in patients aged ≥60 years, with a median age at diagnosis of approximately 70 years 1. The NCCN guidelines corroborate this, reporting that 54% of AML patients are diagnosed at ≥65 years of age, with approximately one-third diagnosed at ≥75 years 2. This makes AML predominantly a disease of the elderly population.
CML Age Distribution
In contrast, CML has a median age at diagnosis of 60-65 years in Europe 3, which is notably younger than AML. While CML incidence does increase with age, the pattern is less pronounced than with AML. The annual incidence of CML is relatively stable at 10-15 cases per million population 3, whereas AML shows a more dramatic age-related increase.
Key Distinguishing Features
The critical difference lies in the steepness of age-related incidence:
- AML shows a marked rise in incidence after age 60, with the aging population contributing to increasing AML incidence 1
- CML maintains a more consistent incidence across age groups, though it does occur more frequently in older adults 3
Mortality and Burden Considerations
AML accounts for the largest number of annual deaths from leukemias in the United States 4, 2, with an estimated 10,590-10,920 deaths annually. This high mortality burden in older adults reflects both the increased incidence and poorer outcomes in this age group, where elderly patients (>60 years) have adverse prognosis and greater susceptibility to treatment complications 5.
Clinical Implications
The predominance of AML in older individuals has important treatment ramifications:
- Older AML patients more frequently present with unfavorable disease subtypes, including AML with myelodysplasia-related changes (19%) and therapy-related AML (7%) 1
- Treatment decisions must account for comorbidities and performance status, which are more prevalent in this older population 6
- The relative incidence of AML with favorable genetic abnormalities decreases with advancing age 1
Bottom line: AML is definitively more common in older individuals than CML, with a higher median age at diagnosis, steeper age-related incidence curve, and greater overall disease burden in the elderly population.